As of May, 14 The EPS for Dermira, Inc. (DERM) Expected At $-1.28

April 17, 2018 - By Russell Jones

Dermira, Inc. (NASDAQ:DERM) Corporate Logo
Big Money Sentiment decreased to 1.27 in Q4 2017. It has change of 0.76, from 2017Q3’s 2.03. The ratio dropped due to Dermira, Inc. positioning: 16 sold and 35 reduced. 25 funds amassed holdings and 40 increased holdings. Investors holded 41.09 million in 2017Q3 but now own 38.81 million shares or 5.56% less.
Price T Rowe Assocs Md has 2.53M shs for 0.01% of their capital. Axa invested in 303,474 shs. Nea Mngmt Limited Liability Corporation, a Maryland-based fund reported 3.51M shs. 1,060 were accumulated by Tower Rech Ltd Llc (Trc). The Missouri-based Amer Century Companies has invested 0% in Dermira, Inc. (NASDAQ:DERM). Tekla Cap Management Limited Liability Corporation owns 268,500 shs. Td Asset Mngmt has invested 0% in Dermira, Inc. (NASDAQ:DERM). Massachusetts-based Wellington Mgmt Gp Llp has invested 0.02% in Dermira, Inc. (NASDAQ:DERM). Employees Retirement Association Of Colorado holds 1,423 shs or 0% of its capital. Moreover, Guggenheim Capital Ltd Liability Com has 0.01% invested in Dermira, Inc. (NASDAQ:DERM). Benjamin F Edwards Co Inc owns 2,975 shs or 0.01% of their US capital. Pnc Services Gru Inc invested in 85 shs or 0% of the stock. New Leaf Venture Prtn Ltd Com invested in 0.79% or 61,109 shs. Credit Suisse Ag holds 38,705 shs. Barclays Public Ltd Co stated it has 11,045 shs or 0% of all its holdings.

Dermira, Inc. registered $1.01 million net activity with 0 buys and 10 insider sales since December 13, 2017. On Thursday, February 1 3,000 shs were sold by BAUER EUGENE A, worth $85,642. WIGGANS THOMAS G had sold 5,000 shs worth $137,566 on Wednesday, December 13. Griffith Christopher M. sold $499,354 worth of stock.

Dermira, Inc. (NASDAQ:DERM)’s earnings report is awaited by WallStreet on May, 14, as reported by RTT. Analysts forecast 62.03 % diference or $-1.28 from the $-0.79 EPS from 2017. -4.48 % EPS growth is what analysts predict. $-1.34 earnings per share was revealed for last [previous quarter]. The stock decreased 1.53% or $0.13 during the last trading session, reaching $8.37.Dermira, Inc. has volume of 280,107 shares. Since April 17, 2017 DERM has declined 77.97% and is downtrending. DERM underperformed by 89.52% the S&P500.

Dermira, Inc. (NASDAQ:DERM) Ratings Coverage

Total analysts of 6 have positions in Dermira (NASDAQ:DERM) as follows: 4 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 67%. Since November 6, 2017 according to StockzIntelligence Inc Dermira has 11 analyst reports. On Wednesday, January 17 the rating was maintained by Leerink Swann with “Buy”. On Tuesday, March 6 the rating was downgraded by Guggenheim to “Neutral”. In Thursday, February 22 report Cantor Fitzgerald maintained it with “Buy” rating and $45.0 target. In Tuesday, November 7 report Needham maintained the stock with “Buy” rating. On Friday, February 23 the firm has “Buy” rating by Mizuho given. On Tuesday, December 12 the stock of Dermira, Inc. (NASDAQ:DERM) earned “Buy” rating by Mizuho. On Tuesday, November 7 the firm earned “Buy” rating by Leerink Swann. On Monday, November 6 Cantor Fitzgerald maintained the shares of DERM in report with “Buy” rating. On Tuesday, December 5 the company was initiated by Guggenheim. On Monday, March 5 Mizuho downgraded the shares of DERM in report to “Hold” rating.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases.The firm is valued at $350.05 million. The company's pipeline includes three late-stage product candidates, such as Glycopyrronium tosylate, an anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; Olumacostat glasaretil, a small-molecule designed to target sebum production, following topical application is in Phase III development for the treatment of acne vulgaris; and lebrikizumab, a novel, humanized monoclonal antibody targeting interleukin 13, for which the firm is planning to initiate a Phase IIb dose-ranging study for the treatment of moderate-to-severe atopic dermatitis.Currently it has negative earnings. It has a licensing agreement with Roche to develop and commercialize lebrikizumab for atopic dermatitis and other potential indications.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: